Sparsentan导致的不良反应怎么治疗？

Introduction: Sparsentan is a dual antagonist of endothelin type A receptor (ET A R) and angiotensin II (Ang II) type 1 receptor (AT 1R), indicated for the reduction of proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Adverse reactions caused by Sparsentan

Adverse reactions include but are not limited to the following:

1. Hepatotoxicity: The use of Sparsentan may cause liver problems, and liver function needs to be monitored regularly.

2. Embryo-fetal toxicity: Based on animal data, use of Sparsentan during pregnancy may cause fetal damage, including birth defects and fetal death, and is contraindicated during pregnancy.

3. Hypotension: Patients taking sparsentan may experience adverse events related to hypotension, including dizziness.

4. Peripheral edema: One of the most common side effects of Sparsentan is peripheral edema.

Also includes anemia, headache, fatigue, nausea, vomiting, diarrhea, weight gain, etc. During the period of using Sparsentan, patients need to undergo regular examinations and monitoring, and pay close attention to their physical condition.

How to treat adverse reactions caused by Sparsentan

1. Hepatotoxicity: It is recommended to conduct further liver function tests and decide whether to continue using Sparsentan as appropriate.

2. Embryo-fetal toxicity: Inform patients who may be pregnant of the potential risks to the fetus, and conduct a pregnancy test before starting treatment, every month during treatment, and 1 month after stopping treatment.

3. Hypotension: Patients at risk of hypotension should consider stopping or adjusting other antihypertensive drugs and maintaining appropriate volume status. If hypotension occurs despite elimination or reduction of other antihypertensive agents, consider dose reduction or interruption of Sparsentan.

Patients should follow the doctor's instructions when using Sparsentan, and conduct relevant examinations and monitoring regularly, and discuss the use of earphones for special groups.

Special population use of Sparsentan

1. Children: Proper research has not yet been conducted on the relationship between the role of Sparsentan in children and age, and the safety and effectiveness of the drug in children have not yet been determined.

2. Elderly: Appropriate studies conducted to date have not demonstrated problems unique to the elderly that would limit the use of Sparsentan in the elderly.

3. Breastfeeding women: There have been no adequate studies in women to determine the risks to the baby of taking this drug during breastfeeding. Please weigh the potential benefits against the potential risks before taking this drug during breastfeeding.